

What's All the Buzz? Urticaria and other Allergy-mediated Skin Conditions

Skin, Bones, Hearts, and Private Parts 2020

Kara N. Roman, MMS, PA-C

Associate Director & Assistant Professor

Midwestern University PA Program, Downers Grove, IL

Learning Objectives:

- Identify common and life-threatening allergy-mediated skin conditions utilizing presenting symptoms and classic physical exam findings
- Discuss confirmatory diagnostic testing in suspected allergic skin diseases
- Outline effective management strategies for allergic skin conditions including urticaria, atopic dermatitis, and contact dermatitis

- **25-year-old female presents to ED-Fast Track**
- Complains of itchy rash that began 1 hour ago on her arms and chest

History

- When did it start?
 - About an hour ago, maybe a few minutes more
- What were you doing at the time?
 - Eating lunch at Panera: fish sandwich, fries, milkshake
 - About 15 minutes after I started eating I began to notice my skin felt funny and itchy, then I noticed the rash and my friend who was with me said I needed to come over here right away
- Is it getting worse?
 - I think it is spreading from my face to my chest and arms
 - It is getting really itchy, almost intolerable
- Associated symptoms?
 - No not much, except I feel a little lightheaded or dizzy
 - No coughing, SOB, abdominal pain, N/V

More History

- Any recent illness?
 - I have a little sinus congestion, but I think it is just my allergies
- Any new exposures (medications, topical products)?
 - New Hawaiian Tropic sunscreen last week
- Have you ever had something like this before?
 - Not really, had a little rash with a bee sting once, but it went away after a few hours
- Any travel?
 - No recent travel outside the country
- Anyone else sick at home/work?
 - Everyone's allergies are bothering them, but no severe illnesses
- History of atopy?
 - SAR, parents and sister with atopy, no asthma

Additional Helpful Information

- Current medications
 - Seasonale OCP
 - Zyrtec for SAR 10 mg at bedtime
 - Vitamin D3 800 IU daily
- Allergies to medications
 - NKDA
- PMH
 - T&A in 1992 for repeated infections, snoring, mouth-breathing
 - SAR – began in grade school, seems to be a little worse in Illinois than in New York where she grew up
- FH
 - Father, 55yo, hypertension, chronic sinus infections, mild kidney dz
 - Mother, 50yo, psoriatic arthritis and psoriasis, eczema as child, hypertension
 - Younger sister, age 22, with SAR, acne, PCOS
 - No FH of DM, cancer, or other significant illnesses

Physical Exam

- Vitals

- Temp 99 degrees F oral, HR 105, RR 22, BP 100/60
- Ht 5'5", Wt 120 #, BMI 19.9

- Skin – see next slide

- HEENT

- NC/AT, PERRL, conjunctiva clear, TMs clr, sl nasal congestion b/l with clear/white d/c, no sinus tenderness, no edema to lips, post o/p and oral mucosa with erythema, no exudate or ulcers

How Would You Describe This?



Physical Examination

- Neck
 - Supple, no LAD, no thyroid enlargement or masses
- Respiratory
 - Very faint wheeze in posterior lung fields b/l on forced expiration, no stridor, no retractions or increased WOB, no rales or rhonchi
- CV
 - Tachycardia, no abnormal rhythm, no murmurs, S1 and S2 are present, no S3 or S4, no gallops, clicks, or rubs
- Extremities
 - Rash noted on arms and legs, no lesions on palms and soles, no edema

Specialized Exam Techniques

- What do you call this reaction, and how was it made?




What is Your Diagnosis?

- Acute urticaria
- Allergic reaction
- Wheezing or bronchospasm

Why?

- Quick onset
- Classic lesions
- History of atopy in self and family
- Eating at restaurant

IgE-mediated Reactions



APC, antigen-presenting cell; IgE, immunoglobulin E; Th, T-helper [cell].

Credit: [Gaurab Karki, Microbiologist Kathmandu, via Online Biology Notes.](#)

Characteristics of Urticaria

- Can occur anywhere on the body
- Patients report intense pruritis, stinging, pins and needles
- Lesions are round to polymorphic, can grow rapidly and coalesce
 - “Puddle in a sea of erythema”
 - “Splash-shaped”
- Well-circumscribed
- Pale to brightly erythematous
- Individual lesions appear quickly (within minutes) and resolve within 24 hrs leaving no residual lesions

Type I Hypersensitivity Reactions: Common Causes

- Food (3%)
 - Big 8: peanuts, tree nuts, dairy, egg, wheat, soy, fish, shellfish
- Infection (49%)
- Hymenoptera venom
 - Bees and wasps
- Latex
 - Especially in persons who work in healthcare with lots of exposure
- Medications (5%)
- Idiopathic (up to 50%)

Labs and Diagnostic Testing in Acute Urticaria

- Acute cases - usually clinical diagnosis
- Allergy referral
 - Skin prick tests
 - Serum protein specific IgE level
 - Oral challenges
- Anaphylaxis
 - Urinary or serum histamine
 - Serum tryptase

Food Allergies: Skin Prick Testing

- Useful screening test with commercial extracts from food with stable proteins
- High rate of false-positives
- Wheals and flares are measured

Food Allergy Diagnostic Testing: IgE Specific Antibody Testing

Food	>95% Positive		~50% Negative	
	sIgE	SPT	sIgE	SPT wheal (mm)
Egg white	≥7 ≥2 if age <2 y	≥7	≤2	≤3
Cow's milk	≥15 ≥5 if age <1 y	≥8	≤2	
Peanut	≥14	≥8	≤2 = history of prior reaction ≤5 = no history of prior reaction	≤3
Fish	≥20			

TABLE 1

Positive predictive value of food-allergen-specific IgE levels by ImmunoCAP

ALLERGEN	SPECIFIC IgE (KU/L)	POSITIVE PREDICTIVE VALUE
Cow's milk (age > 2 years) (age ≤ 2 years)	15	95%
	5	95%
Egg (age > 2 years) (age ≤ 2 years)	7	98%
	2	95%
Fish	20	100%
Peanuts	14	100%
Soybean	30	73%
Tree nuts	15	95%
Wheat	26	74%

Limitations: majority of the data initially accrued in pediatric populations; food allergy not validated by double-blind, placebo-controlled oral food challenge in all cases; statistical tools used to calculate positive predictive values not identical in all studies

ADAPTED FROM SAMPSON HA. UPDATE ON FOOD ALLERGY. J ALLERGY CLIN IMMUNOL 2004; 113:805-819, WITH PERMISSION FROM ELSEVIER.

Sampson HA, et al. Food allergy: A practice parameter update—2014, Journal of Allergy and Clinical Immunology, Volume 134, Issue 5, 2014, Pages 1016-1025.e43, ISSN 0091-6749, <https://doi.org/10.1016/j.jaci.2014.05.013>.

<http://www.sciencedirect.com/science/article/pii/S0091674914006721>

Who should be tested with serum IgE?

- All individuals with severe, persisting, or recurrent possible “allergic symptoms”
- Individuals with need for continuous prophylactic treatment
 - To include: infants, children with cutaneous disease, persistent GI symptoms, recurrent wheezing, otitis, rhinitis, or asthma
- To determine feasibility and safety of an oral challenge

Labs and Diagnostics in Chronic Urticaria (> 6 wks)

- Skin biopsy - vasculitis
- CBC with differential
- ESR/CRP
- TSH
- LFTs
- Urinalysis

Treatment of Acute Urticaria

- Antihistamines
 - First generation
 - Second generation
- H2-Blockers
- Corticosteroids
 - Methylprednisolone
 - Prednisone
 - Dexamethasone

Medication Orders

- Diphenhydramine 50 mg PO once
 - First generation H1 blocker with more rapid onset than second generation (also comes in parenteral form if pt is unable to tolerate PO)
- Ranitidine 150 mg PO once
 - H2 blocker
- Prednisone 40 mg PO once
 - Corticosteroid

- How long until she should feel better?

You Re-check Patient in 15 minutes

- Hives seem to be lightening

BUT

- She reports numbness and tingling in her lips and tongue, tightness in her chest, and a feeling of lightheadedness

How Would You Describe this Skin Finding?



How Would You Describe this Skin Finding?



Angioedema

Characteristics of Angioedema

- Primarily affects the face, lips, mouth, upper airways, extremities
 - Areas where there is loose tissue
 - Spares dependent areas
 - Often asymmetric
- Localized non-pitting edema
- May be painful and warm
- Develops rapidly, but takes up to 72 hours to resolve
- It may be a sign of an advancing/deeper allergic reaction
 - Leaking of plasma cells into the mucosa or skin
 - Urticaria that occurs in the deeper layers of the skin and mucosa

Could This Be Anaphylaxis?

- Acute onset of illness
 - With the involvement of skin, mucosal tissue or both and at least one of the following:
 - Respiratory compromise
 - Reduced blood pressure
 - Evidence of end-organ dysfunction
- If pt is known to have allergy than just 2 of the following:
 - Involvement of skin or mucous membranes
 - Respiratory compromise
 - Reduced BP or end-organ dysfunction
 - Persistent GI symptoms
- Low BP is KEY
 - Adults: < 90 mm Hg systolic

Next Steps

- Re-check vital signs – BP 90/60
 - Hypotension is key to a diagnosis of anaphylaxis
- ECG monitoring
 - NSR, HR 110
- Oxygen
- IV access and fluids
- Respiratory exam
 - Increased wheezing noted, pulse ox 94%
- Cardiac exam

Additional Medications Needed

- Epinephrine
- Bronchodilator

Additional Medications

- Intramuscular injection of Epinephrine
 - See dosing on next slide
- Inhaled Beta₂-agonist
 - Albuterol Inhalation Solution 0.5%
 - 2.5 mg (0.5mL in 2.5mL of sterile normal saline)
 - Nebulized



ADAM.



Epinephrine Dosing

- 1:1000 dilution contains 1 mg/ml
- Weight calculated dosage 0.01 mg/kg
- Intramuscular Injection in lateral thigh
 - > 12 years 0.3-0.5mg 0.5 ml of 1:1000
 - 6-12 years 0.25 mg 0.25 ml of 1:1000
 - 6 mo to 6 yrs 0.12 mg 0.12 ml of 1:1000
 - Under 6 mo 0.05 mg 0.05 ml of 1:1000
- Auto-injectors
 - < 25 kg 0.15 mg
 - > 25 kg 0.30 mg

Follow-up

- Your patient is monitored in the ED for the next 4-6 hours
- Angioedema resolves
- Wheezing disappears
- Hives fade
- BP stabilizes at 110/70, HR 88, RR 18
- Discharged with instructions to
 - Avoid any food that was eaten at Panera and follow-up with Allergist/Immunologist
 - Rx for self-injectable Epinephrine
 - Rx for oral corticosteroid for 3-5 days
 - Instructions to continue OTC antihistamine for 3-5 days
 - Cetirizine 10 mg PO QHS/BID for 5 days

Treatment of IgE-Mediated Allergies Day-by-Day

- Avoidance of triggers
 - avoidance of aspirin, NSAIDs, alcohol is recommended
- Self-injectable epinephrine (multiple)
- Allergy Action Plan
- Medical alert jewelry

Newer Therapies

- OIT – Oral Immunotherapy
 - Daily small doses of antigen to induce tolerance
 - Total and specific IgE levels decrease over time
 - May have to continue indefinitely to maintain tolerance
- Omalizumab (Xolair)
 - Anti-IgE therapy that decreases total available IgE and fills receptor sites on mast cells and basophils to decrease the patient's response to antigen exposure
 - Subcutaneous injection with dosing and interval based on pt weight and IgE levels (usually every 2-4 weeks, 150-375 mg)
 - Used in chronic urticaria and hereditary angioedema

New Guidelines for Introducing Foods

LEAP and LEAP-On Purposeful Early Feeding

- Introduce highly allergenic foods (CM, hen's egg, peanut, tree nuts, fish, and shellfish) when children are at least four months and developmentally ready to consume complimentary foods
- Begin with cereals, fruits, vegetables to ensure readiness
- Then add one of the allergenic foods at home with an oral antihistamine available
- If there is no reaction, the food can be introduced in gradually increasing amounts
- Also acceptable is the referral to allergist and SPT for patients with a confirmed IgE-mediated allergy, moderate to severe atopic dermatitis, family history of atopic dermatitis

[https://www.annallergy.org/article/S1081-1206\(16\)31164-4/fulltext](https://www.annallergy.org/article/S1081-1206(16)31164-4/fulltext)

Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases—sponsored expert panel. Togias, Alkis et al., Annals of Allergy, Asthma & Immunology, Volume 118, Issue 2, 166 - 173.e7, Feb 2017

- **18-year-old female cross country runner presents to Urgent Care for evaluation of a diffuse and pruritic rash**
- It began on the forearms 3-4 days ago as shown several hours after taking a run with her dog on a wooded trail, but has since spread to the face, neck and torso.
- The patient denies exposure to any new products, foods, or any change in her routine.

What is Your Diagnosis?

- Contact Dermatitis

Why?

Dermatitis – Irritant and **Allergic**

- Delayed, Type IV hypersensitivity immunologic reaction
- Risk factors
 - Occupational exposures – health professionals, chemical industry, beauticians/hairdressers, machinists, construction workers
 - Adults most typically affected
 - Comorbidities – atopic dermatitis

What allergen is most likely responsible for this localized contact dermatitis presentation?

History

- Location and duration
- Size of lesions
- Itching
- Prior episodes
- Occupational or non-occupational exposure
- New chemicals, including detergents, creams, household cleaners
- Cosmetics including makeup, shampoo, body wash
- Previous treatment and response to treatments
- Foreign objects such as jewelry, buttons
- New food exposure or preservatives

ACD/ICD

- Intensely pruritic rash
- Papular, vesicular, bullae
- Pattern of exposure of allergen
 - Linear – poison ivy
 - Round – buttons, earrings

ACD



Which of the following would be the most appropriate management for moderate ACD (like the patient with poison ivy)?

- A. Methylprednisolone dose pack
- B. Prednisone 40 mg per day for 4 days then 20 mg per day for 4 days and then 10 mg for 4 days
- C. Topical pimecrolimus 1% cream twice daily for 7 days
- D. Topical mometasone cream four times daily to affected areas for 7 days
- E. Cetirizine 10 mg twice daily for 7-10 days

Which of the following would be the most appropriate management for moderate ACD (like the patient with poison ivy)?

- A. Methylprednisolone dose pack
- B. Prednisone 40 mg per day for 4 days then 20 mg per day for 4 days and then 10 mg for 4 days**
- C. Topical pimecrolimus 1% cream twice daily for 7 days
- D. Topical mometasone cream four times daily to affected areas for 7 days
- E. Cetirizine 10 mg twice daily for 7-10 days

Allergic Contact Dermatitis Treatment


- Epicutaneous patch testing if unsure of source or need confirmation
- Avoidance
- Medium to high-potency topical corticosteroids
- Topical emollients
- Cool compresses or oatmeal baths
- Systemic corticosteroids if moderate to severe
 - Especially important in plant-derived etiology as rebound dermatitis is common (may need 2-3 weeks of steroid with taper)

Patch Testing

Avoidance

- 2 computer-generated databases available in US
- List products that are free of the suspected allergens
 - Contact Allergen Management Program/CAMP – American Contact Dermatitis Society <https://www.contactderm.org/>
 - Mayo Clinic's SkinSAFE Database <https://www.skisafeproducts.com/>

E Online | C...



Search SkinSAFE

Sign In or Register

For Skin Health Professionals

Generate Safe Shopping Lists for Your Patients

Quickly generate safe product shopping lists based on your patient's unique allergens

Print and generate PDFs of relevant product categories

Automatically invite patients to view their shopping list on SkinSAFE

Easy access to manage and edit existing patient lists

Start Your 30 Day Free Trial >

It only takes seconds to input allergens and generate a shopping list for your patients. We've even put together preset lists of allergens to pick from based on the most popular patch tests.

New Shopping List Start Over



7 Allergens 7 mandatory and 6 optional Cross-Reactor-Groups

Edit Allergens Save to Presets Print Shopping List Save Patient & Send

Excluded Allergens: Bacitracin, Cobalt Chloride, Formaldehyde, neomycin sulfate, nickel sulfate, Quaternium-15, Triacortol 21 Pivalate

Skin Safe - 5657 Matching Products

Search Products in THIS Patient's List

Category	Sub-Cat	Brand	OTC / Rx	Sort
		3m Avagard Foaming Hand Antiseptic		3M
		3m Cavilon Antifungal Cream, 3m Pharmaceuticals		3M

Avoidance

- Nickel spot test – dimethyl-glyoxime test

- **6-month-old male with a facial and body rash for the past several weeks, seems itchy, not sleeping well at night, both parents with seasonal allergies, just began solid food supplementation to breast feeding**



What is Your Diagnosis?

- Atopic dermatitis

Why?

Atopic Dermatitis

- Intermittent or persistent course
- Onset most common by 5 years of age
- ~5-20% of school-aged children
- ~10% of adults



INFANTS



TODDLERS/PRESCHOOLERS



SCHOOL-AGE CHILDREN



ADULTS

Hebert AA. *J Manag Care Med*. 2018;21:47-51.

Images from: <https://www.dermnetnz.org/topics/atopic-eczema/>

Atopic Dermatitis: The Facts

- **Pathogenesis:** Genetic defects allow weakened epidermal barrier, immune hypersensitivity with increased T-cell response and elevated IgE levels, increased sensitivity to *S. aureus* superantigens
- **Atopic Triad** = AD, Allergies, Asthma
 - FH of atopy

Atopic Dermatitis: The Findings/Features

Clinical Features

- Pruritus, dry skin
- Flexural or cheeks/extensors distribution
- Erythematous papules, plaques, vesicles
- Lichenification
- Superinfections - impetigo, molluscum

Atopic Dermatitis Diagnosis

Essential Features [must be present]

- Pruritus
- Eczema (acute, subacute, chronic)
 - Typical morphology and age-specific patterns
 - Facial, neck, and extensor involvement in infants/children
 - Current or previous flexural lesions in any age group
 - Sparing the groin and axillary regions
 - Chronic or relapsing history

Important Features [adds support to diagnosis]

- Early age of onset
- Atopy
 - Personal and/or family history
 - IgE reactivity
- Xerosis




Basic Management

- Skin care: moisturizers, warm baths, antiseptic measures
- Anti-inflammatory agents
 - Topical corticosteroids (TCS)
 - Overall good safety profile
 - Potential side effects: purpura, telangiectasia, striae, focal hypertrichosis, skin atrophy; systemic exposure
 - Topical phosphodiesterase inhibitor – crisaborole 2% ointment
 - Topical calcineurin inhibitors (TCI)
Tacrolimus (0.03%, 0.1%); pimecrolimus (1%)
 - No risk for cutaneous atrophy
 - Potential side effects: local reactions (stinging and burning)
 - Black box warning, long-term safety not established (malignancy?)

Crisaborole: Phosphodiesterase 4 Inhibitor

Targeting PDE-4 reduces the production of proinflammatory mediators in AD





Adapted by Infograph-ed, LLC from Paller AS, et al. *J Allergy Clin Immunol.* 2017;140:633-643.

FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207695s000lbl.pdf. Accessed April 2, 2018.

Crisaborole

- Phosphodiesterase 4 inhibitor; targeting PDE-4 reduces the production of pro-inflammatory mediators in AD
- FDA approved December 2016
- For topical treatment of mild-to-moderate AD in patients ≥ 2 yrs
- Ointment, 2%; apply twice daily to affected areas

Significant Improvement with Crisaborole 2% Ointment vs Vehicle (control)



Patients ≥ 2 yrs with mild-to-moderate AD


Primary efficacy end point of success in ISGA score at day 29:

clear (0) or almost clear (1) with a 2-grade or more improvement from baseline

Data from phase 3 studies

Adapted from Paller AS, et al. *J Am Acad Dermatol.* 2016;75:494-503.

Improvement in Pruritus with Crisaborole 2% Ointment vs Vehicle (control)



Patients \geq 2 yrs with mild-to-moderate AD

Data from phase 3 studies

Adapted from Paller AS, et al. *J Am Acad Dermatol.* 2016;75:494-503.

Crisaborole Safety Profile

Adverse Event	Crisaborole Ointment (n = 1012) (%)	Vehicle (n = 499) (%)
Treatment-related AE		
Application site pain	4.4	1.2
Treatment-emergent AE		
Gastrointestinal disorders	2.7	2.4
Vomiting	1.5	1.0
Application site pain	4.4	1.2
Application site pruritus	0.5	1.2
Pyrexia	1.9	1.4
Infections and infestations	11.7	11.8
Nasopharyngitis	1.8	1.2
Staphylococcal skin infection	0.1	1.0
Upper respiratory tract infection	3.0	3.0

A 34-year-old woman has longstanding AD

- She is in your clinic today for an acute worsening of her disease over the past week
 - She has had increased pruritus and now has multiple painful areas within the involved skin
 - She always bathes with gentle cleansers, and has been applying petrolatum jelly and TCS (triamcinolone acetonide, 0.1% ointment) without improvement



Secondary *S. aureus* Infections in AD

- Common complication in patients with AD
- **Purulent exudate and pustules on skin examination** may suggest a diagnosis of secondary bacterial infection over inflammation from dermatitis
- Systemic antibiotics **ARE** appropriate with clinical evidence of bacterial infection in patients with AD, in addition to standard treatments including TCS

Step-Care Management of AD

Mild

Severe

Maintenance Treatment	Non-lesional	Mild		Moderate	Severe
	<p>BASIC MANAGEMENT Skin Care</p> <ul style="list-style-type: none"> Moisturizer, liberal and frequent (petrolatum-based moisturizer) Warm baths or showers using non-soap cleansers, usually once daily and followed by a moisturizer (even on clean areas) <p>Trigger Avoidance</p> <ul style="list-style-type: none"> Proven allergens and common irritants (eg, soaps, wool, temperature extremes) Consider comorbidities 	<p>BASIC MANAGEMENT Skin Care</p> <ul style="list-style-type: none"> Moisturizer, liberal and frequent (choice per patient preference) Warm baths or showers, usually once daily and followed by moisturizer (even on clear areas) <p>Antiseptic Measures</p> <ul style="list-style-type: none"> Dilute bleach bath (or equivalent) \leqx/week according to severity (especially with recurrent infections) Antibiotics, if needed <p>Trigger Avoidance</p> <ul style="list-style-type: none"> Proven allergens and common irritants (eg, soaps, wool temperature extremes) Consider comorbidities 	<p>BASIC MANAGEMENT + TOPICAL ANTI-INFLAMMATORY MEDICATION Apply of areas of previous or potential symptoms (aka flare)</p> <p>Maintenance TCS</p> <ul style="list-style-type: none"> Low potency 1x-2x daily (including face) Medium potency 1x-2x weekly (except face) <p>OR Maintenance TCI (pimecrolimus, tacrolimus)</p> <ul style="list-style-type: none"> 1x-2x daily 2x-3x weekly (not an indicated dosage) <p>OR Crisaborole 2%¹</p> <ul style="list-style-type: none"> 2x daily 	<p>BASIC MANAGEMENT + REFERRAL to AD Specialist</p> <p>Phototherapy</p> <p>Dupilumab²</p> <p>Systemic Immunosuppressants</p> <ul style="list-style-type: none"> Cyclosporine A³ Methotrexate³ Mycophenolate mofetil³ Azathioprine³ Corticosteroids⁴ <p>Consider acute tx for some patients to help gain control:</p> <ul style="list-style-type: none"> Wet wrap therapy Short-term hospitalization 	
Acute Treatment	<p>Apply TCS to Inflamed Skin</p> <p>Low to medium potency TCS 2x daily for 3-7 days beyond clearance [Consider TCI, crisaborole]</p>		<p>Apply TCS to Inflamed Skin</p> <p>Medium to high potency TCS 2x daily for 3-7 days beyond clearance [Consider TCI, crisaborole] If not Resolved in 7 Days, Consider </p>		<ul style="list-style-type: none"> Non-adherence Infection Misdiagnosis Contact allergy to medications Referral

¹For patients \geq 2 yrs with mild to moderate AD

²For patients at least 12 yrs with moderate to severe AD

³Not FDA approved for AD

⁴Not recommended for long-term maintenance


Other Treatments

- Oral Antihistamines
 - Short-term, intermittent use for sleep loss secondary to pruritus
 - Use in conjunction with topical therapies
- Phototherapy
 - Second Line
 - Can be used as maintenance therapy in those with chronic disease
 - NB-UVB
 - BB-UVB
 - PUVA
 - UVAB
- Dupilimab


Dupilumab

- Human monoclonal IgG4 antibody, inhibits IL-4 and IL-13 signal transduction through competitively binding to the shared α subunit of the IL-4 receptor
- FDA approved March 2017
- Adults and adolescents aged 12 and older with moderate-to-severe AD; can be used with or without TCS
- SQ injection; initial dose of 600 mg (two 300 mg injections; different sites), followed by 300 mg every other week
- Biologics: cost considerations

Dupilumab Phase 3 Efficacy vs Placebo: Primary Endpoint



Dupilumab Phase 3 Efficacy: Improvement in Pruritus



Dupilumab: Common Adverse Events

Adverse event	Week 16						Week 52		
	SOLO1			SOLO2			CHRONOS		
	Placebo (n = 222)	Dupilumab q2w (n = 229)	Dupilumab qw (n = 218)	Placebo (n = 234)	Dupilumab q2w (n = 236)	Dupilumab qw (n = 237)	Placebo + TCS (n = 315)	Dupilumab q2w + TCS (n = 110)	Dupilumab qw + TCS (n = 315)
Nasopharyngitis	8	10	11	9	8	8	19	23	19
Upper respiratory tract infection	2	3	5	2	3	4	10	10	14
Injection site reactions	6	8	19	6	14	13	8	15	19
Conjunctivitis	1	5	3	<1	4	4	8	14	19
Skin infections	8	6	6	11	6	6	18	11	8
Exacerbation of AD	30	13	10	35	14	16	41	14	13

Gooderman MJ, et al. *J Am Acad Dermatol*. 2018;78:S28-36.

FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf. Accessed April 2, 2018.

Medications for Atopic Dermatitis in Phase II and III

- Phase II & III
 - Tralokinumab – blocks IL-13 alone - injection
 - Upadacitinib - Janus kinase (JAK-1) inhibitor – oral
 - Baricitinib – JAK-1 and JAK-2 inhibitor – oral
 - Tofacitinib – JAK1/2 inhibitor - topical

Atopic Dermatitis Action Plan

Patient Name: _____

Date: _____

Use your action plan as a guide for how your health care team wants you to manage your AD, and what to do when your condition changes

	Mild Signs/Symptoms	Moderate Signs/Symptoms	Severe Signs/Symptoms
Bathing or showering			
Daily skin-care routine			
Symptom management			
Additional information			
Support strategies			

Selected References/Resources

- Jafilan, L, James, C. Urticaria and Allergy-Mediated Conditions. *Prim Care Clin Office Pract* 42 (2015) 473-483.
- Schneider L et al. Atopic dermatitis: A practice parameter update 2012. American Academy of Allergy, Asthma & Immunology, 2013.
- Fonacier L. et al. Contact Dermatitis: A practice parameter-update 2015. American Academy of Allergy, Asthma & Immunology, 2015.
- Togias A et al. Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. American Academy of Allergy, Asthma & Immunology, 2016.
- Boguniewicz M, et al. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape, *Ann Allergy Asthma Immunol*. 2018;120:10-22.